μ-Opiate receptor agonists - A new pharmacological approach to prevent motion sickness?

British Journal of Clinical Pharmacology

Volumn 61, Issue 1, 2006, Pages 27-30

  Otto, Bärbel ^a   Riepl, Rudolf L ^a,b   Otto, Carsten ^a   Klose, Joachim ^a   Enck, Paul ^c   Klosterhalfen, Sibylle ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Kreiskrankenhaus   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Opiate agonist; Loperamide; Motion sickness; Nausea; Stress hormones

Indexed keywords

CORTICOTROPIN; HORMONE; LOPERAMIDE; MU OPIATE RECEPTOR AGONIST; PLACEBO; VASOPRESSIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEAD MOVEMENT; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MALE; MOTION SICKNESS; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; ROTATION; VASOPRESSIN BLOOD LEVEL;

ADRENOCORTICOTROPIC HORMONE; ADULT; CROSS-OVER STUDIES; FEMALE; HUMANS; LOPERAMIDE; MALE; MOTION SICKNESS; NAUSEA; RECEPTORS, OPIOID, MU; ROTATION; SINGLE-BLIND METHOD; VASOPRESSINS;

EID: 33644926730     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02505.x     Document Type: Article

References (14)

1. Golding JF Gresty MA. Motion sickness Curr Opin Neurol 2005 18 29 34
2. Drummer C Stromeyer H Riepl RL König A Strollo F Lang RE Maass H Rocker L Gerzer R. Hormonal changes during parabolic flight: implications on the development of motion sickness Aviat Space Envir Med 1990 61 821 8
3. Giagnoni G Casiraghi L Senini R Revel L Parolaro D Sala M Gori E. Loperamide: evidence of interaction with μ and opiod receptors Life Sci 1993 33 315 8
4. Dumitrascu DL Stanculete M Mitrea I Dumitrascu DM Farcas A. The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea Rom J Intern Med 2004 42 191 7
5. Auernhammer CJ Stalla GK Lange M Pfeiffer A Müller OA. Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro J Clin Endocrinol Metab 1992 75 552 7
6. Riepl RL Reichardt B Auernhammer CJ Beier G Schopohl J Stalla GK Lehnert P. Suppression of vagus-mediated pancreatic polypeptide release by the μ-opiate receptor agonist loperamide Br J Clin Pharmacol 1996 46 371 7
7. Ooms LAA Degryse AD Janssen PAJ. Mechanism of action of loperamide Scand J Gastroenterol 1984 96 145 55
8. Klosterhalfen S Rüttgers A Kumrey E Otto B Stockhorst U Riepl RL Probst T Enck P. Pavlovian conditioning of taste aversion using a motion sickness paradigm Psychosom Med 2000 62 671 7
9. Rohleder N Otto B Wolf JM Klose J Kirschbaum C Enck P Klosterhalfen S. Adaptation of endocrine and inflammatory responses to repeated nauseogenic body rotation Psychoneuroendocrinology 2005 in press
10. Grundy D Reid K. The physiology of nausea and vomiting. In The Physiology of the Gastrointestinal Tract Johnson LR. New York Raven Press 1994 879 901
11. Kohl RL MacDonald SM. New pharmacological approaches to the prevention of space/motion sickness J Clin Pharmacol 1991 31 934 6
12. Laduron PM. Axonal transport of opiate receptors in capsicin-sensitive neurons Brain Res 1984 294 157 60
13. Reichardt B Üngörgil S Riepl RL Schedlowski M Lehnert P Enck P. ACTH- and ADH-profiles during motion sickness screened by continuous blood sampling Gastroenterology 1997 112 A811
14. Feldman M Samson WK O'Dorisio TM. Apomorhine-induced nausea in humans: release of vasopressin and pancreatic polypeptide Gastroenterology 1988 95 721 6